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Dengue virus is a single-stranded RNA virus in the genus
lavivirus,  family Flaviridae.  There are four distinct serotypes
DENV1–DENV4). They are antigenically diverse and only share
bout 60–75% identity at the amino acid level [1]. Due to genetic
ariations leading to changes in viral ﬁtness, virulence, and trans-
ission, serotypes and lineages may  manifest different patterns
f clinical disease and severity. The mature spherical dengue viral
article contains multiple copies of the three structural proteins
capsid, C, prM, the precursor of membrane, M,  protein and enve-
ope, E), as well as a host-derived membrane bilayer and a single
opy of a positive-sense, single-stranded RNA genome. Human
ntibodies raised against the DEN virion are mostly targeted at the
 and prM proteins.
The virus is transmitted to humans by infectious bites of Aedes
osquitoes, in particular Ae. aegypti but also Ae. albopictus.  These
ectors are urban day-biting mosquitoes, such that insecticide
reated bednets, which have been very important for malaria con-
rol, are ineffective [2]. Infected humans are the main carriers
nd multipliers of the virus, which then transmit DENV to unin-
ected mosquitoes for subsequent transmission. The geographic
istribution of dengue is determined in large part by the vector
 This is an Open Access article published under the CC BY 3.0 IGO license which
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264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open acce[3]. During the past ﬁve decades, the incidence of dengue world-
wide has increased 30-fold [4]. In 2013 the WHO  ranked dengue
as the fastest spreading vector-borne viral disease, with an epi-
demic potential. This expansion is believed to be due to global trade
(increased transportation and expansion of the vectors), increased
global travel (importations of dengue virus to new areas), and
urbanization (multiple transmission opportunities from an infected
mosquito), possibly enhanced by global warming [5]. Today, all ﬁve
WHO  regions are affected by dengue, with nearly 4 billion people
believed to be at risk of dengue infection. The numbers of dengue
cases submitted to WHO  are underreported and many cases are
misclassiﬁed because illness is mild or cannot be differentiated
from other viral diseases that manifest high fever [6]. One recent
modelling estimate suggests 390 million dengue infections occur
globally each year, of which 96 million are clinical, and up to one
million considered severe [7]. Dengue control is a major public
health priority in disease endemic countries. However, the burden
of disease in many regions, particularly Africa, is poorly understood.
In endemic areas, dengue has been traditionally a pediatric dis-
ease of children less than 15 years of age. However, in some settings
there has been a shift toward older age groups; it has been sug-
gested this is related to changing demographics, including smaller
susceptible birth cohorts and a larger immune aging population [8].
Dengue can be diagnosed either by virus isolation, serology
(MAC-ELISA, IgG ELISA, NS1 ELISA, and PRNT), or molecular meth-
ods (RT-PCR). PCR is considered the gold-standard for dengue
diagnosis (80–90% sensitivity and 95% speciﬁcity if applied in the
adequate time window), as serological tests suffer from cross-
reactivity, variable sensitivity by timing of specimen collection, and
the need for multiple samples (IgG acute and convalescent samples)
[9,10]. Due to limited capacity for PCR around the world, deﬁnitive
dengue diagnosis is difﬁcult in many settings.
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Clinical dengue, in particular during epidemics, puts a signif-
cant strain on health care facilities. WHO  classiﬁes dengue into
wo categories, dengue (with or without warning signs) and severe
engue [9]. Dengue without warning signs can still lead to signiﬁ-
ant patient discomfort and debilitation from high fever, vomiting,
yalgia, and joint pain lasting 3–7 days, leading to school absen-
eeism and loss of work. Because it is difﬁcult to know which dengue
ases will become severe, non-severe patients are often admitted
o the hospital for monitoring. Severe dengue can be life threaten-
ng due to plasma leaking, ﬂuid accumulation, respiratory distress,
evere bleeding, and/or organ impairment. Through improved sup-
ortive clinical case management, case fatality rates from severe
engue have decreased from more than 20% to less than 1% [11,12].
roper maintenance of the patient’s body ﬂuid volume is critical to
atient success.
The strain on the health system and wider economic conse-
uences of non-severe and severe dengue are signiﬁcant. The cost
f illness includes lost wages and decreased productivity as well
s care-seeking and direct medical expenses. Sixty percent of the
conomic strain is attributable to indirect costs [13]. The global eco-
omic burden is not well described, but in the Americas alone it is
stimated at $2.1 billion USD each year.
Natural immunity to wild-type infection is not completely
nderstood. Humans infected with one serotype of dengue appear
o remain protected for the rest of their life to subsequent
ymptomatic infection with the infecting serotype (homotypic
mmunity) [14]. Following a ﬁrst clinically manifested infection,
here is a period of cross-protection (heterotypic immunity) against
ymptomatic infection with the other three serotypes for approx-
mately two years [15]. As cross-protection wanes, individuals
ho have only had a primary infection are at an increased risk
f severe dengue with a secondary infection of a heterologous
erotype [16]. It is commonly believed that this increased risk is
ue to antibody-dependent enhancement of infection, but other
echanisms may  contribute [1]. Following a secondary infection,
ymptomatic dengue due to a third or fourth infection is rare.
hus it is presumed that a secondary infection reinforces non-type
peciﬁc immunity that provides additional protection against the
emaining serotypes (multitypic immunity) [14]. This phenomenon
ith wild type infection has been an important consideration for
he strategy to develop a vaccine and the necessary follow up in
linical trials [17].
. Overview of current efforts
.1. EITHER Vaccines currently available and their limitations OR
iological feasibility for vaccine development
In December, 2015, the ﬁrst dengue vaccine, Dengvaxia® (CYD-
DV) developed by Sanoﬁ Pasteur, was licensed in Mexico [18]. The
accine was licensed in individuals 9–45 years living in endemic
reas. CYD-TDV has since been licensed by several endemic
ountries National Regulatory Authorities (NRA).
CYD-TDV is a 3-dose live recombinant tetravalent dengue vac-
ine administered on a 0/6/12 month schedule. It is based on the
F17D backbone, which is also the basis for the licensed JE vaccine
MOJEV [19]. CYD-TDV includes all three structural proteins, but
ecause of the YF backbone, there are no dengue non-structural
roteins included. This vaccine has been evaluated in two large
ivotal Phase 3 trials in 5 countries in Asia and 5 countries in
atin America, in participants aged 2–16 across the two trials
20,21]. Pooled vaccine efﬁcacy against symptomatic virologically-
onﬁrmed dengue (VCD) of any serotype in the year starting 1
onth after the third dose was 59.2% (95%CI 52.3, 65.0) [22].
accine efﬁcacy varied by participant age, serostatus at baseline,
everity of dengue disease, and infecting serotype. Vaccine efﬁcacy4 (2016) 2934–2938 2935
was higher against serotypes 3 and 4 (71.6% and 76.9%, respectively)
than against serotypes 1 and 2 (54.7% and 43.0%, respectively), with
the lower conﬁdence bound above zero for all serotypes. Surpris-
ingly, vaccine efﬁcacy was  substantially higher among participants
who had already been exposed to dengue (pooled VE from immuno-
logical subset: 78.2%, 95% CI 65.4, 86.3) compared with participants
who were naive at baseline (pooled VE: 38.1%, 95% CI −3.4, 62.9).
Interim results from long-term safety follow up demonstrated an
elevated risk of hospitalization and severe dengue among 2–5 year
old participants (at vaccination) in the third year after receipt of the
ﬁrst dose (RR = 7.45, 95% CI 1.15, 313.80). This younger age group
was thus not included in the initial indication. No safety signals
were identiﬁed in older age groups.
The mechanism behind the imbalance seen in the youngest age
group is not currently understood, although there are a number of
hypotheses, including age-speciﬁc susceptibility to severe disease,
serostatus at baseline, waning immunity, and clustering of cases in
the CYD group [23,24]. While differences in risk are associated with
age, there may  be factors in addition to or highly correlated with age
that are important. There is a need to better characterize and assess
the potential increased risk of dengue among some vaccinees look-
ing at both characteristics of the vaccine and vaccinees, which will
also inform any implications for other vaccine candidates [25]. An
optimal pediatric vaccine would need to elicit long-term protection
against dengue from all four serotypes in seronaive individuals, and
hence should have strong immunological priming capacity against
all four DENV serotypes.
In addition, six other candidates are in clinical development
using a variety of technological approaches (Table 1). A strong case
for the feasibility of developing a dengue vaccine can be made based
on the assumed life-long homotypic immunity conferred by natural
infection [14]. Due to the theoretical risk of immune enhancement,
the dogma has been that a tetravalent vaccine inducing a balanced
immune response was  needed [26]. The interim results of long-
term follow up of CYD-TDV show these concerns to be relevant
(though not conﬁrmed), and ongoing/future development efforts
will need to have practices in place to closely monitor for changes
in risk, including in subgroups, and make all efforts to ensure the
safety of trial participants [27].
2.2. General approaches to vaccine development for this disease
for low and middle income country markets
Many dengue-endemic countries are middle-high income
economies and provide a large market to drive development. Can-
didates under development are being designed primarily for use in
endemic settings, which are predominantly low and middle income
countries. For this reason and for easier implementation into immu-
nization programs, there are efforts to minimize the number of
doses needed, ideally for single-dose vaccines. One candidate vac-
cines have also been studied for having a low cost of goods [28].
Given the age distribution of symptomatic dengue, which is quite
broad and dependent upon on the transmission setting, there is
attention both to vaccine use in young children as well as in adults.
There is consensus that a vaccine that can be provided in early child-
hood is needed for those countries in which substantial disease in
childhood would require early vaccination. Live attenuated candi-
dates under development have ongoing age de-escalation studies
with a target lower bound of 1 or 2 years due to interference
with maternally derived antibodies and ADE and are both currently
being evaluated as single dose vaccines [29–32].3. Technical and regulatory assessment
While many dengue vaccine trials are conducted under US
Investigational New Drug (IND) supervision, dengue vaccines have
2936 K.S. Vannice et al. / Vaccine 34 (2016) 2934–2938
Table 1
Development status of current vaccine candidates.
Candidate name/Identiﬁer Developer Preclinicala Phase I Phase II Phase III
CYD-TDV
Live recombinant based on a yellow fever
vaccine 17D backbone
Sanoﬁ Pasteur X X X X
TV003/TV005
Tetravalent live, attenuated/recombinant (whole
virus DENV1-3 and recombinant DENV2 in
DENV4 backbone)
US National Institutes of Health
and Butantan (with licenses to
other manufacturers)
X X X X
DENVax
Tetravalent live, attenuated/recombinant (whole
virus DENV2 and recombinant DENV1/3/4 in
DENV2 backbone)
Takeda X X X
TDENV  PIV
Tetravalent puriﬁed inactivated vaccine
GSK/US WRAIR/Fiocruz X X
DEN-80E
Tetravalent E protein subunit vaccine
Merck X X
TVDV
Tetravalent “shufﬂed” prM/E expressed from
plasmid vector DNA vaccine
US NMRC X Xb
TLAV-TPIV
Heterologous prime-boost with live attenuated
tetravalent, live attenuated vaccine and
tetravalent alum-adjuvanted puriﬁed
inactivated vaccine
US WRAIR X X
EDIII-p64k fusion proteins and EDIII-capsid fusion
proteins expressed in E. coli
IPK/CIGB X
Bivalent 80E-STF2 fusion proteins expressed in
baculovirus/insect cells
VaxInnate X
Tetravalent consensus EDIII protein expressed in
E. coli
NHRI X
prM/E expressed from plasmid vector DNA vaccine US CDC X
EDIII-HBsAg VLPs or ectoE-based VLPs expressed
in P. pastoris
ICGEB X
Tetravalent EDIII and DENV-1 ectoM expressed
from live-attenuated measles virus vector
Themis Bioscience/Institut
Pasteur
X
E85 expressed from single-cycle VEE virus vector Global Vaccines X
Psoralen-inactivated DENV US NMRC X
Puriﬁed inactivated DENV FIOCRUZ X
Inactivated virus (+VEE-particle adjuvant) Global Vaccines X
DEN/DEN chimeric viruses, live, attenuated Chiang Mai University/Mahidol
University/NSTDA/BioNet-Asia
X
DEN host range mutations, live, attenuated Arbovax X
DEN-SA 14 14 2, live, attenuated Beijing Institute X
DEN targeted mutation (2′-O-methyltransferase
mutant), live, attenuated
Novartis Institute for Tropical
Diseases/Agency for Science,
Technology and Research,
Singapore
X
Plasmid vector expressing prM/E (prime) and live
attenuated DENV (boost)
NMRC/WRAIR X
DENV prM/E expressed from live attenuated
chimeric YF 17D/DEN virus with DNA vaccine
FIOCRUZ X
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a Evaluation ongoing or completed in NHPs.
b Clinical evaluation of monovalent candidate only.
een considered independently by NRAs in endemic countries for
linical trials and registration without reliance on WHO  prequal-
ﬁcation. WHO  has provided support to NRAs that ﬁrst received
he CYD-TDV dengue vaccine dossier to assist informed decision-
aking for vaccine registration.
In 2007, WHO  developed guidelines for the clinical evaluation
f dengue vaccine in endemic countries and recommended symp-
omatic virologically-conﬁrmed dengue as the primary endpoint
17]. Such an end-point requires an active surveillance system
hat captures all febrile illness to avoid missing detection of mild
engue, which may  never present to a hospital. Other secondary
ndpoints were suggested, such as efﬁcacy against each of the four
istinct virus types; efﬁcacy after the ﬁrst of two or more doses of
accine; effect on duration of hospitalization for dengue; severity of
aboratory-conﬁrmed dengue cases; vaccine efﬁcacy against “pos-
ible” or “probable” dengue infection. The 2007 guidelines were
ater on integrated into WHO’s regulatory guidance [33].e pre-deﬁned template for PD-VAC.
No correlate of protection for dengue has been identiﬁed as yet,
so large efﬁcacy trials are required at this time [17,34], although
some correlation has been described between vaccine-induced
neutralizing antibody titers (as measured by PRNT50) and protec-
tion from disease for a given serotype [35]. However, data from both
clinical trials as well as observational studies suggest that thresh-
olds may  be different across vaccines as well as serotypes, and there
has not been a clear match between seroconversion as measured
by PRNT50 and protection from disease [36,37]. Cellular immu-
nity may  also contribute to protection. It has been demonstrated
that the majority of CD8+ T cell epitopes are located in the NS pro-
teins and that CD8+ T cells have a role in the protective immune
response against dengue [38]. New neutralization and CMI  assays
are currently being developed and validated.
There are only 3 natural hosts for dengue; humans, non-human
primates, and mosquitoes. Nonhuman primates may  be infected
with dengue but do not manifest clinical symptoms; nonhuman
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[2] Achee NL, Gould F, Perkins TA, Reiner Jr RC, Morrison AC, Ritchie SA, et al. AK.S. Vannice et al. / Va
rimate studies have been used to demonstrate protection against
iremia [39]. Other animal models are of limited value. Human chal-
enge models, both of infection and disease, are at the early stages
nd should provide useful data for candidate selection in the future,
s well as possibly identifying correlates of protection [40–42].
ecent data from one candidate (TV003, described below) showed
00% protection against viremia, rash, and neutropenia following
hallenge with an attenuated DENV2 virus 6 months post vaccina-
ion [43]. Many candidates are in the process of being evaluated or
ave plans for evaluation using a human challenge model.
. Status of vaccine R&D activities
.1. Clinical pipeline
In addition to CYD-TDV, two other tetravalent live recombinant
accines, TV003/TV005 and DENVax, have just begun or are close to
eginning Phase 3 trials and do contain dengue virus non-structural
roteins for at least one serotype [44].
TV003 and TV005 (which are identical except for the dosing level
f the dengue 2 component) were developed by the US National
nstitutes of Health and are based on wild-type strains with genetic
utations to attenuate the virus [44]. Several monovalent candi-
ates were ﬁrst tested in Phase 1 trials to optimize each of the
our vaccine virus strains [45]. Vaccine virus serotypes 1, 3, and 4
re based on complete viruses, while serotype 2 is a recombinant
irus based on the serotype 4 vaccine strain with the structural
roteins replaced by those of serotype 2. One dose of TV005
licits seroconversion rates over 90% against each serotype, and
0% of ﬂavivirus-naive recipients mounted a tetravalent response
46]. TV003 or TV005 has been licensed to several manufacturers,
ncluding Butantan, VaBiotech, and Merck [47]. Phase 2 studies are
nderway in Brazil and Thailand, and a Phase 3 trial led by Butantan
egan in February, 2016, in Brazil [32,47].
TDV (formerly DENVax) is also a live recombinant vaccine,
eveloped by Takeda (originally Inviragen). This tetravalent formu-
ation includes a whole attenuated DEN2 virus and recombinant
EN1, DEN3, and DEN4 using the DEN2 background [48]. There
ave been a number of ongoing and completed Phase 1 and Phase 2
rials in both endemic and non-endemic settings, evaluating 2 doses
f a variety of formulations and routes of administration (including
raditional needle-syringe mechanism, a needle-less injector, and
 needle-free Pharmaject Injector) [44,49–51]. Two doses adminis-
ered 90 days apart induced tetravalent seroconversion rates of 60%
n dengue-naïve subjects [51]. An ongoing study 1800 children in
sia and Latin America evaluating three different dosing schedules
day 0 only, 0 and 3 months, day 0 and 1 year) will help determine
he optimal dosing schedule for TDV [29]. A Phase 3 trial is expected
o begin soon.
A number of other candidates and approaches have been or
re currently under evaluation in Phase 1 trials (Table 1) [44].
hese include a tetravalent puriﬁed inactivated vaccine (GSK) [52],
 tetravalent recombinant subunit vaccine based on the dengue
ild-type premembrane and truncated envelope protein (Merck)
53,54], a monovalent plasmid DNA vaccine (US Navy Medical
esearch Center) [55], and an inactivated vaccine/live attenuated
accine heterologous prime boost (Walter Reed Army Institute of
esearch) [56].
.2. Preclinical pipelineThe preclinical pipeline for dengue vaccines includes both
onventional as well as novel technological approaches, includ-
ng recombinant subunit vaccines, DNA vaccines, VLP vaccines,
irus-vectored vaccines, puriﬁed inactivated virus vaccines, live4 (2016) 2934–2938 2937
attenuated virus vaccines, heterologous prime-boost approaches,
and simultaneous administration with two  technologically differ-
ent vaccine candidates (Table 1) [57]. Approximately 20 candidates
have been or are in the process of being evaluated in NHP mod-
els, with some expected to move soon into the clinic. Some novel
approaches include a measles vaccine viral vector (Themis Bio-
science) [58] and the Japanese encephalitis SA14-14-2 vaccine viral
vector (Beijing Institute) [59]. Fiocruz is exploring simultaneous
vaccination with a recombinant YF17D vaccine viral vector together
with a DNA vaccine [60].
5. Likelihood for ﬁnancing
Dengue was  not prioritized in the 2013 Gavi Vaccine Investment
Strategy (VIS) due to reasons including the limited mortality and
DALYs attributable to dengue as compared with other vaccines in
the portfolio, in addition to uncertainty about the dengue vaccine
pipeline at the time of the review [61]. It is expected to be reviewed
again as part of the 2018 VIS. A better understanding of disease
burden in Africa as well as better quantiﬁcation of the economic
burden of dengue may  elevate dengue as a priority for ﬁnancing by
Gavi and others. It is expected that most dengue-endemic countries
would need to fund the vaccine procurement and implementation
independently.
6. Conclusions
The dengue vaccine clinical landscape is very dynamic. Despite
multiple hurdles to vaccine development, tremendous progress has
been made, and there is now a licensed dengue vaccine. There is still
a signiﬁcant research agenda to understand the mode of action of
licensed and candidate dengue vaccines, and to ensure that vacci-
nees are not put at increased risk of dengue at some time period
following vaccination. Efforts are also needed to be able to protect
younger children through vaccination. Continued efforts in dengue
vaccine development are critical to address the growing burden of
dengue worldwide. A safe, effective and affordable dengue vaccine
would represent a major advance for the control of the disease and
could be an important tool for reaching the WHO  goal of reducing
dengue morbidity by at least 25% and mortality by at least 50% by
2020.
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